{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:04:28Z","timestamp":1785423868673,"version":"3.56.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,27]],"date-time":"2016-04-27T00:00:00Z","timestamp":1461715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Heart Journal"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.ihj.2016.04.023","type":"journal-article","created":{"date-parts":[[2016,5,22]],"date-time":"2016-05-22T16:56:46Z","timestamp":1463936206000},"page":"803-808","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Metabolic manipulation in dilated cardiomyopathy: Assessing the role of trimetazidine"],"prefix":"10.1016","volume":"68","author":[{"given":"Suman","family":"Jatain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roopali","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeep","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyendra","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pravin","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ihj.2016.04.023_bib0180","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1093\/eurjhf\/hfp029","article-title":"Understanding the \u2018epidemic of heart failure\u2019: a systematic review of trends in determinants of heart failure","volume":"11","author":"Najafi","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ihj.2016.04.023_bib0185","article-title":"Metabolic modulation: a new therapeutic target in treatment of heart failure","author":"Palaniswamy","year":"2010","journal-title":"Am J Ther"},{"key":"10.1016\/j.ihj.2016.04.023_bib0190","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0008-6363(96)00245-3","article-title":"Regulation of myocardial carbohydrate metabolism under normal and ischemic conditions. Potential for pharmacological interventions","volume":"33","author":"Stanley","year":"1997","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ihj.2016.04.023_bib0195","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1172\/JCI113822","article-title":"Myocardial substrate utilization during exercise in humans. Dual carbon-labeled carbohydrate isotope experiments","volume":"82","author":"Gertz","year":"1988","journal-title":"J Clin Investig"},{"issue":"4","key":"10.1016\/j.ihj.2016.04.023_bib0200","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1161\/01.CIR.99.4.578","article-title":"Glucose for the heart","volume":"99","author":"Depre","year":"1999","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ihj.2016.04.023_bib0205","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0022-3565(25)10243-7","article-title":"An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts","volume":"264","author":"Lopaschuk","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ihj.2016.04.023_bib0210","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0735-1097(02)01967-8","article-title":"Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy","volume":"40","author":"Davila-Roman","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2016.04.023_bib0215","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.81.2.153","article-title":"Assessment of myocardial fatty acid metabolic abnormalities in patients with idiopathic dilated cardiomyopathy using 123I BMIPP SPECT: correlation with clinicopathological findings and clinical course","volume":"81","author":"Yazaki","year":"1999","journal-title":"Heart"},{"key":"10.1016\/j.ihj.2016.04.023_bib0220","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/01.RES.86.5.580","article-title":"The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase","volume":"86","author":"Kantor","year":"2000","journal-title":"Circ Res"},{"key":"10.1016\/j.ihj.2016.04.023_bib0225","first-page":"1775","article-title":"Efficacy of trimetazidine in stable effort angina. Double blind study against placebo","volume":"15","author":"Passeron","year":"1986","journal-title":"Presse Med"},{"issue":"Suppl. 1","key":"10.1016\/j.ihj.2016.04.023_bib0230","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1177\/107424840400900105","article-title":"Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials","volume":"9","author":"Chaitman","year":"2004","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.ihj.2016.04.023_bib0235","first-page":"97","article-title":"Anti-ischemia effects of trimetazidine: 31P-NMR spectroscopy in the isolated rat heart","volume":"286","author":"Lavanchy","year":"1987","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"10.1016\/j.ihj.2016.04.023_bib0240","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1023\/A:1007731219206","article-title":"Effects of trimetazidine on metabolic and functional recovery of postischemic rat hearts","volume":"12","author":"Allibardi","year":"1998","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.ihj.2016.04.023_bib0245","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1476-5381.1996.tb15268.x","article-title":"Effects of trimetazidine on pHi in the rat isolated ventricular myocyte","volume":"117","author":"Lagadic-Gossmann","year":"1996","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ihj.2016.04.023_bib0250","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/BF02125756","article-title":"Internal Ph, Na+, and Ca2+ regulation by trimetazidine during cardiac cell acidosis","volume":"1","author":"Renaud","year":"1988","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.ihj.2016.04.023_bib0255","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1365-2125.1985.tb05047.x","article-title":"Effects of trimetazidine on membrane damage induced by oxygen free radicals in human red cells","volume":"20","author":"Maridonneau-Parini","year":"1985","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ihj.2016.04.023_bib0260","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/oxfordjournals.eurheartj.a059685","article-title":"Therapeutic value of a cardioprotective agent in patients with severe ischemic cardiomyopathy","volume":"11","author":"Brottier","year":"1990","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2016.04.023_bib0265","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1053\/euhj.2001.2653","article-title":"Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy","volume":"22","author":"Belardinelli","year":"2001","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2016.04.023_bib0270","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1016\/S0002-8703(03)00415-0","article-title":"Short and long term beneficial effects of partial free fatty acid inhibition in diabetic patients with ischemic dilated cardiomyopathy","volume":"146","author":"Fragasso","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.ihj.2016.04.023_bib0275","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.ehj.2004.06.034","article-title":"Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease","volume":"25","author":"Vitale","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2016.04.023_bib0280","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/hrt.2003.031310","article-title":"Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy","volume":"91","author":"Di Napoli","year":"2005","journal-title":"Heart"},{"key":"10.1016\/j.ihj.2016.04.023_bib0285","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jacc.2006.03.060","article-title":"A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure","volume":"48","author":"Fragasso","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2016.04.023_bib0290","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/eurheartj\/ehi816","article-title":"Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine\/adenosine triphosphate ratio in patients with heart failure","volume":"27","author":"Fragasso","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2016.04.023_bib0295","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1161\/CIRCULATIONAHA.108.778019","article-title":"Trimetazidine: a metabolic modulator. Has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy","volume":"118","author":"Tuunanen","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2016.04.023_bib0300","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1136\/heart.83.6.634","article-title":"The left ventricular dysfunction questionnaire (LVD-36): reliability, validity, and responsiveness","volume":"83","author":"O\u2019Leary","year":"2000","journal-title":"Heart"},{"key":"10.1016\/j.ihj.2016.04.023_bib0305","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/0002-9149(80)90122-8","article-title":"Noninvasive quantification of left ventricular wall stress: validation of method and application to assessment of chronic pressure overload","volume":"45","author":"Quinones","year":"1980","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ihj.2016.04.023_bib0310","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1161\/01.CIR.55.4.613","article-title":"Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method","volume":"55","author":"Devereux","year":"1977","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2016.04.023_bib0315","first-page":"135","article-title":"New non-invasive index for combined systolic and diastolic ventricular function","volume":"26","author":"Tei","year":"1995","journal-title":"J Cardiol"},{"issue":"1","key":"10.1016\/j.ihj.2016.04.023_bib0320","first-page":"2","article-title":"Effect of trimetazidine on left ventricular function in heart failure secondary to ischemic heart disease","volume":"8","author":"Khan","year":"2010","journal-title":"Gomal J Med Sci"},{"key":"10.1016\/j.ihj.2016.04.023_bib0325","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1161\/01.CIR.102.17.2070","article-title":"The effects of b1-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction: a double-blind, placebo-controlled, positron-emission tomography study","volume":"102","author":"Beanlands","year":"2000","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.ihj.2016.04.023_bib0330","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.lfs.2012.03.015","article-title":"The effect of trimetazidine on cardiac function in diabetic patients with idiopathic dilated cardiomyopathy","volume":"92","author":"Zhao","year":"2013","journal-title":"Life Sci"},{"key":"10.1016\/j.ihj.2016.04.023_bib0335","doi-asserted-by":"crossref","first-page":"602e1","DOI":"10.1016\/j.ahj.2007.06.033","article-title":"Beneficial effects of trimetazidine treatment on exercise tolerance and B-type natriuretic peptide and troponin T plasma levels in patients with stable ischemic cardiomyopathy","volume":"154","author":"Napoli","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.ihj.2016.04.023_bib0340","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jacc.2011.11.027","article-title":"Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis","volume":"59","author":"Zhang","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2016.04.023_bib0345","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/hrt.2010.208751","article-title":"Trimetazidine: a meta-analysis of randomized controlled trials in heart failure","volume":"97","author":"Gao","year":"2011","journal-title":"Heart"},{"issue":"3","key":"10.1016\/j.ihj.2016.04.023_bib0350","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ijcard.2012.09.123","article-title":"Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: results from an international multicentre retrospective cohort study","volume":"163","author":"Fragasso","year":"2013","journal-title":"Int J Cardiol"}],"container-title":["Indian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001948321630075X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001948321630075X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T18:15:24Z","timestamp":1748974524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001948321630075X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S001948321630075X"],"URL":"https:\/\/doi.org\/10.1016\/j.ihj.2016.04.023","relation":{},"ISSN":["0019-4832"],"issn-type":[{"value":"0019-4832","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic manipulation in dilated cardiomyopathy: Assessing the role of trimetazidine","name":"articletitle","label":"Article Title"},{"value":"Indian Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ihj.2016.04.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Cardiological Society of India. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}